Aflibercept for Treating Diabetic Macular Oedema (TA346)

Technology Appraisal Guidance No. 346

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Aflibercept solution for injection is recommended as an option for treating visual impairment caused by diabetic macular oedema only if:

  • the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
  • the company provides aflibercept with the discount agreed in the patient access scheme.

1.2 People whose treatment with aflibercept is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue aflibercept until they and their NHS clinician consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Aflibercept for treating diabetic macular oedema

Issue Date: July 2015

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in